Watts C R, Truong D D, Nye C
Department of Communication Sciences and Disorders, James Madison University, Harrisonberg, Virginia 22840, USA.
J Neural Transm (Vienna). 2008;115(4):625-30. doi: 10.1007/s00702-007-0757-x. Epub 2007 Jun 14.
The practice of evidence-based medicine promotes use of the knowledge ascertained from high quality research designs. The objective of this review was to determine what evidence has been provided from high quality research designs (e.g., randomized control trials or high quality prospective, matched group cohort studies), through December of 2006, relative to the effectiveness of botulinum toxin for treating spasmodic dysphonia. Results of the review indicated that no new high quality (Class I or Class II) studies have been published since 2001. One Class I study has been published since 1973, which found significant treatment effects for acoustic and perceptual variables of vocal function. Four Class II studies have been published during this same time frame, all finding significant treatment effects, though the nature of studied factors was variable between investigations. Based on the quality of evidence scale used, botulinum toxin can be considered an effective treatment for adductor spasmodic dysphonia.
循证医学实践促进了从高质量研究设计中所获知识的应用。本综述的目的是确定截至2006年12月，高质量研究设计（如随机对照试验或高质量前瞻性配对组队列研究）提供了哪些关于肉毒杆菌毒素治疗痉挛性发音障碍有效性的证据。综述结果表明，自2001年以来，没有新的高质量（I类或II类）研究发表。自1973年以来发表了一项I类研究，该研究发现肉毒杆菌毒素对嗓音功能的声学和感知变量有显著治疗效果。在同一时期发表了四项II类研究，均发现有显著治疗效果，尽管各研究中所研究因素的性质有所不同。根据所使用的证据质量量表，肉毒杆菌毒素可被认为是治疗内收型痉挛性发音障碍的有效疗法。
